BioCentury
ARTICLE | Financial News

Ahead of Phase II, TP raises $80M mezzanine round

October 19, 2018 12:26 PM UTC

Oncology company TP Therapeutics Inc. (San Diego, Calif.) raised $80 million in a mezzanine round and promoted Athena Countouriotis to CEO from CMO as the company readies to begin a potentially registrational Phase II study of lead program repotrectinib.

Countouriotis, who also was appointed to TP's board, told BioCentury the company's pipeline was designed to tackle treatment resistances that emerge from available therapies. "The candidates' unique 3D structures address potential treatment resistance because they are smaller, more compact, and the way that they bind within the kinase doesn't cause as much steric interference as other kinases do," she said. ...